Division of Takeda Pharmaceutical Co. Ltd.
Latest From CytoMed Inc.
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
James J Feeney, VP, Sr. Dir., Bus. Dev.
Grace C Yeh, PhD, VP, Product Dev. & CSO
- Contact Info
Phone: (617) 661-3400
215 First Street
Cambridge, MA 02142-1221
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.